<DOC>
	<DOCNO>NCT00730288</DOCNO>
	<brief_summary>To evaluate effect previous flavivirus exposure safety immunogenicity ChimeriVax™ dengue tetravalent vaccine Primary Objectives : - To describe safety one injection ChimeriVax™ dengue tetravalent vaccine . - To describe immune response dengue one injection ChimeriVax™ dengue tetravalent vaccine</brief_summary>
	<brief_title>Study ChimeriVax™ Dengue Tetravalent Vaccine Adult Subjects</brief_title>
	<detailed_description>This study evaluate dengue tetravalent vaccine formulation subject age 18 40 year previously immunise dengue YF vaccine .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Hemorrhagic Fevers , Viral</mesh_term>
	<mesh_term>Severe Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 18 40 year day inclusion . Informed consent form sign . For woman , inability bear child negative serum pregnancy test . Completed oneyear followup Study DIV12 . Able attend schedule visit comply trial procedure . For woman childbearing potential : use effective method contraception abstinence least four week prior vaccination least four week vaccination . Exclusion Criteria : History thymic pathology ( thymoma ) , thymectomy , myasthenia gravis . Breastfeeding . Systemic hypersensitivity vaccine component history lifethreatening reaction trial vaccine vaccine contain substance . Previous flavivirus vaccination , e.g . Japanese encephalitis yellow fever . Current abuse alcohol drug addiction may interfere subject 's ability comply trial procedure . Planned participation another clinical trial present trial period . History flavivirus infection ( confirm either clinically , serologically microbiologically ) . Congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede six month , longterm systemic corticosteroid therapy . Chronic illness stage could interfere trial conduct completion . Blood bloodderived product receive past three month . Vaccination plan four week follow trial vaccination . Flavivirus vaccination plan present trial period . Planned travel present trial period area high dengue endemicity . Subject deprive freedom administrative court order , emergency setting , hospitalise without his/her consent . Participation another clinical trial four week precede trial vaccination . Any vaccination four week precede trial vaccination . Human Immunodeficiency Virus ( HIV ) , Hepatitis B ( Ag HBs ) Hepatitis C ( HC ) seropositivity blood sample take screening . Laboratory abnormality consider clinically significant upon Investigator 's judgement blood sample take screening . Positive flavivirus serological test blood sample take screening ( Controls ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Dengue fever</keyword>
	<keyword>Dengue hemorrhagic fever</keyword>
	<keyword>Dengue virus</keyword>
</DOC>